HeartBeam to Attend Industry and Investor Conferences, Sept 4-10, 2025

HeartBeam, a medical technology company, announced that its CEO and CFO will attend industry and investor conferences in September 2025. The company will meet with strategic partners and update investors on its progress towards commercialization. HeartBeam will showcase its FDA-cleared HeartBeam System, a cable-free device capable of collecting ECG signals in 3D for arrhythmia assessment. The company will also present new data comparing the performance of its AI algorithm on standard and non-coplanar ECG signals.

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company dedicated to transforming cardiac care, has announced that its CEO Robert Eno and CFO Timothy Cruickshank will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in September 2025. During these conferences, the executives will meet with strategic and industry partners and update investors on the company's progress towards commercialization.

The MDB Investor Summit 2025 will be held at the Old Parkland, Nurse’s Quarters Building in Dallas, TX on September 4, 2025. HeartBeam will participate in a CEO Small Group Session, Big Idea Updates and Q&A, and conduct live demos of its FDA-cleared HeartBeam System. The cleared HeartBeam System is a cable-free, credit card-sized device capable of collecting ECG signals in 3D (from three non-coplanar directions) for arrhythmia assessment [1].

HRX Live 2025 will be held in Atlanta, GA, from September 4-6, 2025. Dr. Joshua Lampert, Cardiac Electrophysiologist and Medical Director of Machine Learning at Mount Sinai Heart in the Mount Sinai Hospital, will present new data comparing the performance of HeartBeam’s AI algorithm on standard 12-lead ECGs and proprietary non-coplanar ECG signals recorded with the HeartBeam System for detecting atrial flutter and fibrillation. The presentation will take place during the AbstractX Happy Hour on September 4 beginning at 5:30 pm Eastern time [1].

The H.C. Wainwright 27th Annual Global Investment Conference will be held at the Lotte New York Palace Hotel in New York, NY from September 8-10, 2025. During the conference, HeartBeam will participate in one-on-one meetings with institutional investors and host a live, in-person presentation on September 9 starting at 5:00 p.m. Eastern time [1].

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The company holds over 20 issued patents related to technology enablement. HeartBeam is focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform [2].

For more information on the MDB Investor Summit 2025, HRX Live 2025, H.C. Wainwright 27th Annual Global Investment Conference, or to schedule a meeting with HeartBeam management, please contact your conference representative or email your request to BEAT@mzgroup.us or call Chris Tyson at (949) 491-8235.

References:
[1] https://www.marketscreener.com/news/heartbeam-to-participate-at-upcoming-industry-and-investor-conferences-september-4-10-2025-ce7c50dfde8af225
[2] https://finance.yahoo.com/news/heartbeams-nasdaq-beat-ip-momentum-193000208.html